Peptide Panel for Chagas Disease Serological Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current serological diagnostic tests for Chagas disease exhibit poor performance, particularly in Central and North America, due to the genetic diversity of Trypanosoma cruzi and limited geographic representation in diagnostic development.
Innovation Solution
Development of novel peptide compositions with antigenic properties specific to Trypanosoma cruzi, comprising specific sequences or their analogs, homologs, or fragments, designed to improve diagnostic accuracy across different geographic regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current serological diagnostic tests are used, then the diagnostic process is simple, but the diagnostic performance (sensitivity and specificity) is poor
Solution Approach 1:
The patent segments the diagnostic test into multiple components: a panel of 12 different peptide antigens instead of a single antigen, allowing detection of diverse T. cruzi strains. Each peptide targets specific conserved regions, and the combined panel approach improves sensitivity and specificity while maintaining a manageable test structure through modular peptide array design
Solution Approach 2:
The patent uses composite peptide compositions comprising multiple different peptides (SEQ ID NO: 1-65) derived from conserved regions of T. cruzi genomes. This composite antigen panel combines epitopes from multiple DTUs, creating a multi-specific diagnostic reagent that improves detection accuracy across diverse geographic strains while building on established serological test platforms
2Adaptability or versatility
If diagnostics are developed using limited geographic range samples, then the development process is manageable, but the diagnostic performance across diverse geographic areas is poor
Solution Approach 1:
The patent creates a universal diagnostic panel that functions across all T. cruzi DTUs and geographic regions. By selecting peptides from conserved genomic regions present in all strains (TcI-TcVI and TcBat), the diagnostic system achieves multi-functionality, detecting antibodies against diverse strains with a single standardized test platform
Solution Approach 2:
The patent changes the antigenic parameters by using synthesized peptides representing conserved regions across all T. cruzi genomes, replacing traditional single-antigen approaches. This parameter change in antigen diversity and conservation level enables the diagnostic to adapt to various geographic strains while maintaining a standardized test protocol
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these peptide compositions in serological tests enhances diagnostic performance by improving sensitivity and specificity, effectively identifying Chagas disease across diverse geographic areas impacted by the disease.
Implementation Method 1
comprising a peptide or a peptide mixture having antigenic properties with respect to Trypanosoma cruzi (T. cruzi)
Data Source
AI summary
The present disclosure provides novel antigenic peptides and peptide mixtures, and methods of use for the detection of T. cruzi antibodies in tissue samples and the diagnosis of Chagas disease in a subject.